ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1783

The Importance of Histopathological Classification of ANCA-Associated Glomerulonephritis in Renal Function and Renal Survival

Valeria Scaglioni1, Marina Scolnik1, Luis J. Catoggio1, Carlos Federico Varela2, Gustavo Greloni2, Silvia Christiansen3 and Enrique R. Soriano1, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ANCA, glomerulonephritis and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose : Histological changes in renal biopsy are the gold standard for establishing the diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). In 2010 a new histopatological classification for ANCA-associated GN (ANCA GN) was developed by an international working group of renal pathologist. The scheme divides ANCA GN into 4 categories: focal (≥50% normal glomeruli), crescentic (≥50% glomeruli with cellular crescents), mixed (<50% normal, <50% crescentic, <50% globally sclerotic glomeruli) and sclerotic (≥50% globally sclerotic glomeruli). It has been demonstrated that these categories at baseline correlate strongly and independently with renal function at 1 and 5-years follow up.

Objective: The aim of this study was to determine whether the new histopathologic classification scheme is associated to changes in renal function and renal survival in a cohort of patients with ANCA associated vasculitis (AAV) who underwent kidney biopsy in a single center.  

Methods:  We included retrospectively all patients with diagnosis of ANCA GN between January 2002 and May 2013 and had at least 1 year of follow-up. Baseline date was defined as the date of the biopsy.  Renal biopsies were reviewed and classified according to the new classification. Serum creatinine, estimated glomerular filtration rate (eGFR) at time of the biopsy, death, requirement of dialysis, use of immune suppression and plasmapheresis at follow up were recorded.

Results: Forty-four patients (77.2% females) were included (table 1). The mean age was 63.7 (SD:17.5). 25 (56.8%) patients were pANCA positive, 14 (31.8%) cANCA positive, and 5 (11.3%) were ANCA negative. Four patients died during first year of follow up (1 within each biopsy category). Among surviving patients, overall mean improvement in eGFR at 1 year was 13.2-ml/min/1.73 m2. Age and sex were not significantly associated with the 1-year eGFR change.  There was a significant difference in the mean change in eGFR at 1 year based on the histopathologic class (table 2). Focal biopsies were associated with the highest eGFR at presentation, whereas crescentic, mixed and sclerotic were associated with lower eGFRs. Crescentic class was associated with the greatest 1-year improvement in eGFR while sclerotic class did not show significant improvement.

Conclusion:  Our study shows association between crescentic class and improvement in eGFR and association between sclerotic class and reduction in eGFR at 1-year. These results support the use of the histopathologic classification in determining renal prognosis of patients with ANCA GN.

TABLE 1

 

Focal

(n 11)

Crescentic

n (14) 

Mixed

n (15)

Sclerotic

n (4)

P

 

 

 

 

 

 

Age, mean (SD)

68.6

(15.4)

54.0

(16.9)

69.2

(15.3)

63.5

(24.5)

.25

Female, n (%)

10

(90.9)

9

(64.2)

12

(80.0)

3   

(75)

 

Baseline eGFR (mL/min/1.73 m2), mean (IQR)

46.9

(12-78)

13.6

(9-17)

33.4

(20-53)

13.4

(6-17)

.0008

Baseline eGFR category (mL/min/1.73 m2), n (%)

 

 

 

 

 

   ≥ 90

2 (18)

0 (0)

0 (0)

0 (0)

 

   60-89

3 (27)

0 (0)

1 (7)

0 (0)

 

   30-59

2 (18)

0 (0)

5 (33)

0 (0)

 

   15-29

1 (9)

6 (43)

6 (40)

2 (50)

 

   < 15

3 (27)

8 (57)

3(20)

2 (50)

 

ANCA immunofluorescence, n (%)

 

 

 

 

 

   cANCA

4 (36)

6 (43)

3 (20)

1 (25)

 

   pANCA

6 (55)

7 (50)

9 (60)

3 (75)

 

   Both negative

1 (9)

1 (7)

3 (20)

0 (0)

 

BVAS at diagnosis, mean (SD)

14.8

(5.5)

16.7

(3.7)

13.4

(5.4)

12.7

(0.9)

.25

Treatments, n (%)

 

 

 

 

 

   Methilprednisolone

8 (66)

14 (100)

8 (53)

2 (50)

 

   Cyclophosphamide

9 (82)

13 (93)

12 (80)

2 (50)

 

   Rituximab

0 (0)

0 (0)

2 (13)

0 (0)

 

   Plasmapheresis

1 (9)

5 (36)

0 (0)

0 (0)

 

Dialysis at diagnosis, n (%)

1 (9)

4 (29)

2 (13)

3 (75)

 

Dialysis at 1 year, n (%)

0 (0)

1 (7.4)

0 (0)

2 (50)

 

TABLE 2

Histologic class

n

Basal  mean eGFR (mL/min/1.73 m2), mean

1 year  mean eGFR (mL/min/1.73 m2), mean

Delta mean eGFR improvement (1year-basal)

Death within 1 year, n (%)

 

 

 

 

 

 

Focal

11

46.9

57.1

5.2*

1 (9.0)

Crescentic

14

13.6

49.7

35.8*#

1 (7.1)

Mixed

15

33.4

46.9

12.1#

1 (6.6)

Sclerotic

4

13.4

12

-1.5

1 (25)

* p=0.008; # p=0.026.


Disclosure:

V. Scaglioni,
None;

M. Scolnik,
None;

L. J. Catoggio,
None;

C. F. Varela,
None;

G. Greloni,
None;

S. Christiansen,
None;

E. R. Soriano,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-importance-of-histopathological-classification-of-anca-associated-glomerulonephritis-in-renal-function-and-renal-survival/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology